Enliven Therapeutics, Inc.
ELVN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.73 | -0.36 | 2.90 | -0.78 |
| FCF Yield | -1.65% | -2.45% | -1.53% | -0.99% |
| EV / EBITDA | -32.40 | -27.88 | -37.20 | -41.95 |
| Quality | ||||
| ROIC | -5.84% | -10.97% | -8.68% | -9.38% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.67 | 0.85 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 28.79% | -40.37% | -40.84% | 40.23% |
| Safety | ||||
| Net Debt / EBITDA | 4.17 | 3.20 | 4.63 | 3.73 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,612.22 | -1,899.73 | -764.43 | -1,146.38 |